市場調查報告書
商品編碼
1408722
喉鏡刀片市場:現況分析與預測(2023-2030)Laryngoscope Blades Market: Current Analysis and Forecast (2023-2030) |
由於尋找潛在診斷系統的產品批准不斷增加,因此喉鏡刀片市場預計在預測期內將以 5.1% 的複合年增長率強勁增長。 例如,2022 年 7 月,高性能一次性內視鏡領先開發商 Zsquare 的首款產品 Zsquare ENT-Flex 鼻喉鏡獲得 FDA 的營銷許可。 其他幾個因素也導致了市場激增,包括產品發布數量的增加、研究投資、患者治療效果的改善以及企業合作關係。 例如,PROACT Medical 於 2022 年 11 月在歐洲市場推出了一系列創新一次性喉鏡。
依類型劃分,市場分為直刀片和彎刀片。 彎曲刀片段由於其窄凸緣可以控制舌頭並減少對牙齦和牙齒的創傷,因此在 2022 年佔據了最高的市場份額。 這種類型的刀片更適合年齡較大的孩子。 對微創診斷的需求不斷增長以及創新產品的推出導致了該領域的顯著增長。 因此,到2022年,彎曲葉片部分將在市場上佔據主要份額。
根據可用性,市場分為一次性和可重複使用。 預計可重複使用部分在預測期內將以最高複合年增長率成長。 這種增長歸因於可重複使用刀片的成本效率和長生命週期。 由於吸煙和酗酒等不良生活方式的改變,導致喉癌和肺癌的發病率增加,以及人們對肺癌和喉癌等慢性病的認識不斷提高,該細分市場獲得了市場主導地位。我是。 例如,美國癌症協會預測,2022年美國將新增約12,470例喉癌病例,其中男性9,820例,女性2,650例。 因此,可重複使用部分預計將在預測期內主導市場。
根據最終用戶,市場分為醫院、門診手術中心等。 醫院類別是根據醫院提供醫療保健的便利性、高素質醫療人員的可用性、先進醫療技術的利用以及世界各地單位數量的多樣化而按醫院分類的。2022 年 市場。 例如,根據美國醫院協會2023年的數據,2022年美國共有6,129家醫院,擁有919,649張臨床床位和34,011,386名住院病患。 醫院領域的市場競爭非常激烈,預計這種情況在可預見的未來仍將持續。 因此,2022年的市場規模將由醫院產業主導。
為了更了解喉鏡刀片產業的市場實施情況,將市場分為北美(美國、加拿大、北美其他地區)、歐洲(德國、英國、法國、西班牙、義大利、歐洲其他地區) 、亞太地區(根據世界其他地區(中國、日本、印度、亞太其他地區)和世界其他地區的全球影響力進行分析。 預計亞太地區在預測期內將以最高複合年增長率成長。 這是由於市場上存在著大公司、癌症發病率不斷上升以及完善的學術研究機構的存在。 印度和中國等國家為臨床研究提供了有吸引力的投資機會,預計將積極推動喉鏡刀片的研發。 因此,由於亞太地區人口規模龐大,預計在預測期內將以更高的複合年增長率成長。
A laryngoscope blade is a medical device used in conjunction with a laryngoscope handle during intubation procedures. It helps visualize the larynx by lifting the tongue and epiglottis, allowing a clear passage for intubation. Blades come in various shapes and sizes to accommodate different patient anatomies and clinical needs. The laryngoscope blade market is growing at a tremendous rate owing to a surge in the number of chronic diseases such as lung and throat cancer. For instance, in 2020, the International Agency for Research on Cancer and the World Health Organization conducted a GLOBOCAN study on global cancer incidence and prevalence. According to the results of the study, there were approximately 308,102 new cases diagnosed in the U.S. Other factors such as increased focus on early detection and prevention, advances in diagnostics, rising product launch and product approval for laryngoscope systems, and a rise in the senior population are driving factors for the market.
The Laryngoscope Blades Market is expected to grow at a strong CAGR of 5.1% during the forecast period owing to the rising product approvals for finding a potential diagnostic system. For instance, in July 2022, a leading developer of high-performance, single-use endoscopes Zsquare, got FDA clearance to market its first product, the Zsquare ENT-Flex Rhinolaryngoscope. Several other factors such as an increased number of product launches, investment in research, improved patient outcomes, and company collaborations are also leading to the surge in the market. For instance, PROACT Medical launched an innovative new line of single-use laryngoscopes in the European market in November 2022.
Based on types, the market is bifurcated into straight blade and curved blade. The curved blade segment held the highest share in the market in the year 2022 owing to its narrower flange which can control the tongue and decrease trauma to the gingiva and teeth. This type of blade is more suitable for older children. The increased need for minimally invasive diagnostics and innovative product launches have led to significant growth in this segment. Hence, the curved blade segment held a significant share of the market in the year 2022.
Based on usability, the market is bifurcated into disposable, and reusable. The reusable segment is expected to grow with the highest CAGR during the forecast period. This growth is attributed to the cost efficiency and longer life cycle of the reusable blades. This segment is gaining market dominance due to an adaptation of a bad lifestyle comprising of smoking and alcohol that has increased the incidences of throat and lung cancers, and increased awareness of chronic conditions such as lung and throat cancer. For instance, the American Cancer Society estimates that in 2022, there will be about 12,470 new cases of laryngeal cancer including 9,820 men and 2,650 women in the U.S. Thus, the reusable segment is expected to gain prominence in the market in the forecast period.
Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals category held the highest share in the market in 2022 attributed to the ease of access to healthcare provided by hospitals, the availability of highly qualified healthcare personnel, the utilization of advanced medical technology, and a diverse number of units all over the globe. For instance, according to the American Hospital Association in 2023, there are in total of 6,129 hospitals in the U.S with 919,649 staffed beds and 34,011,386 hospital admissions in the year 2022. The market for the hospital segment is highly competitive and is projected to remain so in the foreseeable future. Thus, the hospital segment held dominance in the market in the year 2022.
For a better understanding of the market adoption of the laryngoscope blades industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with the highest CAGR during the forecast period. This is due to the presence of major players in the market, the increasing incidence of cancers, and the presence of well-established academic and research institutes. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for laryngoscope blades. Hence, given the large population size of APAC, it is expected to grow with a high CAGR during the forecast period.
Some of the major players operating in the market include: Teleflex Incorporated; Olympus Corporation; Ambu A/S; HOYA Corporation; Stryker; Henke Sass Wolf GmbH; FUJIFILM Corporation; Hartwell Medical LLC; Medtronic; Smiths Group plc.